Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Bulletin Originals

Set Alert for Originals
What's Next?

What’s Next? Five Things To Look Out For In June

Generics Bulletin previews the most noteworthy and anticipated events for June 2024.

Biosimilars Generic Drugs

AAM Backs FDA’s Proposal For Skinny-Label Safe Harbors

AAM expressed its support for the FDA’s attempt to protect generics and biosimilar companies and their products with skinny labels that carve out patented indications. Meanwhile, the Senate Committee’s hearing on drug pricing gets mixed opinions.

Intellectual Property Legal Issues

What’s Next? Five Things To Look Out For In May

Generics Bulletin previews the most noteworthy and anticipated events for May 2024.

Generic Drugs Biosimilars

What’s Next? Five Things To Look Out For In April

Generics Bulletin previews the most noteworthy and anticipated events for April 2024.

Biosimilars Generic Drugs
See All
Interviews

Pfizer Calls For Sustainable Approach To Ensure Viability Of Biosimilars Market

Global biosimilars player Pfizer is calling for a more sustainable approach to the market to ensure its long-term viability. In the second part of an exclusive interview, Barry Chester, the firm’s global commercial lead for supportive care oncology, tells Generics Bulletin where the company sees room for improvement.

Biosimilars Strategy

‘We’ve Got The Broadest Pure-Play Oncology Portfolio In The industry’ – Pfizer Talks Biosimilars

Pfizer is one of the leading players in the global biosimilars market. Barry Chester, the firm’s global commercial lead for supportive care oncology, talks to Generics Bulletin about how the business fits into the firm’s wider interests, in the first part of an exclusive interview.

Biosimilars Strategy

‘Keytruda? We Believe Opdivo Is The Better Choice’: Xbrane’s CEO Martin Åmark

The CEO of Xbrane Biopharma, a Swedish firm focused solely on biosimilar development using a partnered model to potentially take its biosimilars across the globe, speaks exclusively to Generics Bulletin about its ambitions and challenges, including the recent setback for its proposed Lucentis biosimilar in the US.

Biosimilars Strategy

Taking European Biosimilars To The Next Level

Europe’s biosimilars market now has many years of progress under its belt. But how can this successful foundation be built upon to make the most of the opportunities on the horizon and achieve even greater access and uptake? In an exclusive interview, Generics Bulletin talks to Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil about the next steps.

Biosimilars Europe
See All
Pricewatch UK

UK Pregabalin Prices Skyrocket In May

Pregabalin topped our table of Biggest Risers in May, in another month of multiple treble-digit-percentage average price increases for the UK generics market.

Generic Drugs Pricing Strategies

UK Generic Price Spikes Ease In April

With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.

Market Intelligence Generic Drugs

Vardenafil Vaults To The Top Of UK Price Rises In March

Price increases from multiple suppliers pushed vardenafil to the top of our Biggest Risers table for March 2024.

Market Intelligence Pricing Strategies

Multiple UK Generics See Triple-Digit Rises In February

A raft of different generics saw their average UK trade price more than double in February 2024, according to the latest figures from market researcher WaveData.

Market Intelligence Pricing Strategies
See All
UsernamePublicRestriction

Register